Inactivated SARS-CoV-2 Vaccine (Vero cell)

BIOLOGICAL3 trials

Sponsors

China National Biotec Group Company Limited, Laboratorio Elea Phoenix S.A., Chinese Academy of Medical Sciences

Conditions

COVID-19COVID-19 Virus Infection

Phase 3

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

CompletedNCT04510207

China National Biotec Group Company LimitedCOVID-19

Start: 2020-07-16End: 2021-12-31Updated: 2023-06-18

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

CompletedNCT04560881

Laboratorio Elea Phoenix S.A.COVID-19 Virus Infection

Start: 2020-09-16End: 2021-12-13Updated: 2022-01-12

The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Chinese Academy of Medical SciencesCOVID-19

Start: 2021-01-28End: 2022-07-31Target: 34020Updated: 2021-02-10

Related Papers

Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi

Vaccines2023-01-308 citations

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

JAMA2021-05-26818 citations

The ‘Vero Cell’ COVID-19 vaccine rollout in Nepal: What we know about the Chinese vaccine development and access?

Journal of Patan Academy of Health Sciences2021-04-298 citations